The premise that not every subject with type 2 diabetes benefits from intensive glycemic control, consequently leads setting up flexible regimens of treatment with diabetes drugs (including insulin) and providing individualized glycemic goals and ongoing professional support [11]. This evidence concerns the gene INS and diabetes mellitus.